Central Trust Company’s Coherus Oncology CHRS Stock Holding History

Central Trust Company’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-80	Closed	-$1K	–	1064
2020 Q2	$1K	Sell	80 -240	-75%	-$4.06K	﹤0.01%	1032
2020 Q1	$5K	Hold	320	–	–	﹤0.01%	970
2019 Q4	$6K	Buy	320 +40	+14%	+$738	﹤0.01%	1020
2019 Q3	$6K	Buy	+280	New	+$5.59K	﹤0.01%	992

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Central Trust Company's CHRS Position: Q3 2020 in Review

Central Trust Company sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 80 shares — an estimated $1K sold.

Central Trust Company first reported a position in CHRS in Q3 2019 and held it in 4 quarters. The position peaked at $6K in Q4 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

Central Trust Company reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
Central Trust Company sold 80 Coherus Oncology shares in Q3 2020, an estimated $1K.
Central Trust Company first reported a position in Coherus Oncology in Q3 2019 and held it in 4 quarters.
Central Trust Company's Coherus Oncology position peaked at $6K in Q4 2019.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on Central Trust Company's 13F filing for Q3 2020, filed 22 Oct 2020.